EMEA-002296-PIP01-17-M02

Table of contents

Key facts

Invented name
Alunbrig
Active substance
brigatinib
Therapeutic area
Oncology
Decision number
P/0483/2020
PIP number
EMEA-002296-PIP01-17-M02
Pharmaceutical form(s)
  • Age-appropriate liquid dosage form
  • Film-coated tablet
Condition(s) / indication(s)
  • Treatment of anaplastic large cell lymphoma
  • Treatment of inflammatory myofibroblastic tumours
  • Treatment of non-small cell lung cancer
Route(s) of administration
Oral use
Contact for public enquiries
Takeda Pharm A/S

E-mail: paediatrics@tgrd.com
Tel. +45 46771111

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

Related content

How useful was this page?

Add your rating